Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Men, Young And Unmarried Ignore Skin Cancer Warnings
Men are twice as likely as women to not protect their skin in the sun, despite more men dying from melanoma than women, according to research due to be released at the British Association of Dermatologists annual conference in Glasgow next month.
generic viagra online
Warning Issued Over Proposed Drug Company Promotion Of Medicines To Public, UK
Drug companies may exploit new rules to promote their products to the public but present it as mere provision of information, according to an editorial published this week in the Drug and Therapeutics Bulletin (DTB).
News of the day
Opinion Piece Criticizes Winfrey For 'Unbalanced' Medical Advice On Hormone Replacement Therapy
Oprah Winfrey "has scored good ratings with her health episodes" of her television show, but "in doing so, she seems to have thrown therapeutic caution to the wind," such as on her shows featuring actress Suzanne Somers" opinions on bioidentical hormone replacement therapy, Salon contributor and physician Rahul Parikh writes in an opinion piece. Somers, while advocating for the use of bioidentical HRT as a safe alternative to traditional HRT for postmenopausal women, said she used "mega-doses of bioidenticals continuously and aggressively," according to Parikh. Parikh writes that Somers, on television and in her 2007 book, "argues that these hormones are more natural, more effective and safer than what doctors prescribe." According to Parikh, "In reality, ...÷ there are no good medical studies to back up those claims."Parikh says that although "what Somers was advocating was radically different from standards of medical care," Winfrey "was not concerned" and even said that Somers ""might be a pioneer,"" Parikh continues. Winfrey billed the episode as part of a ""great debate"" on hormone therapy, but she "didn"t ask about whether [Somers"] super-hormone regimen could have contributed to Somers" history of breast cancer"; "her hysterectomy, the result of pre-cancerous changes in her uterus from her use of HRT"; or the "validity of Somers" book"s s, many of whom are neither experts in women"s health or endocrinology, nor board-certified physicians, nor experienced researchers," Parikh states. He adds, "It"s not that Winfrey doesn"t try to maintain medical credibility in her shows," but "her efforts seem subpar," noting that her show "reaches millions of people, while each doctor can reach only one patient at a time." Parikh concludes, "That could easily be corrected by Winfrey providing more thought and balance in her medical advice" (Parikh, Salon, 5/15).
Sexual Health

Agendia Opens CLIA-Registered U.S. Genomics Laboratory

Agendia, a world leader in molecular cancer diagnostics, announced the opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The laboratory is fully-licensed and compliant with the Clinical Laboratory Improvements Amendments (CLIA) as administered by the Centers for Medicare and Medicaid Services (CMS). In addition to opening its U.S. cancer genomics laboratory, Agendia has over the past months made several key additions to its domestic-based senior executive team. The team consists of Dr. Richard Bender, Chief Medical Officer, Mr. Daniel Forche, Vice President of Sales & Marketing, Mr. Alan B. Carter, Vice President of Global Business Development, and pathologist Dr. Chynel Henning, Laboratory Director. "Our new genomics lab"s capacity will allow us to meet the increasing demand for MammaPrint across the United States and give physicians and patients optimal test result turnaround and unmatched service and support," noted Jan Groen, Ph.D., Chief Operating Officer. "This expansion places us in an excellent position to continue making advancements in molecular cancer diagnostics and equip oncologists with powerful tools to use in the fight against breast cancer." Dr. Bernhard Sixt, President and Chief Executive Officer, added, "the opening of the Huntington Beach laboratory and the appointment of our U.S.-based commercial team provide a strong basis for our U.S. operations and for Agendia"s next phase of growth. Our enhanced domestic capabilities will help us to further drive adoption of MammaPrint, and place us in an even better position to collaborate with a growing number of clinical, academic, and industrial partners here in the U.S." Dr. Bender has more than 30 years of medical and professional experience as a practicing oncologist and director of several oncology programs. Dr. Bender has served as Medical Director of the Hematology/Oncology Program at Quest Diagnostics, Director of Medical Oncology and Hematology at Kaiser Permanente Medical Group, Director of Strategic Development in Medical Oncology/Hematology at Johnson & Johnson, and as an investigator at the National Cancer Institute and Scripps Clinic and Research Foundation. Currently, Dr. Bender serves as an expert reviewer in oncology for the Medical Board of California, co-Editor of Anti-Cancer Drugs, an international journal on anti-cancer agents, and as a clinical instructor in medicine at the University of California, Irvine School of Medicine. Mr. Forche brings more than 18 years of sales, marketing and commercial leadership experience in the diagnostics arena. Prior to joining Agendia, Mr. Forche was the Senior Vice President of Sales and Marketing for Insight Health Corporation, a national leader in diagnostic imaging services. He also served as Vice President of Marketing at US LABS, an industry leader in cancer diagnostic and genomic testing services, and has held sales and marketing management roles at Ventana Medical Systems (now Roche) and Abbott Laboratories. Mr. Carter joins Agendia with 25 years of global business development experience from a number of top-tier life sciences companies such as BioTrove, Celera, Applied Biosystems, and Perkin Elmer. At Agendia, he oversees ongoing strategic alliances within the bio-pharmaceutical sector and collaboration with partners interested in Agendia"s expanding molecular diagnostics portfolio. Chynel Henning, M.D., Ph.D., FASCP, FCAP, joins Agendia with more than 30 years of experience as a laboratory director. He is currently also Director of National Cyto-Path Laboratories and Professional Pathology Medical Group Laboratory, both in Long Beach, California; and Director of the Laboratory and Department of Pathology at the Miracle Mile Medical Center, Los Angeles. Dr. Henning is a Fellow of the American Society of Clinical Pathologists and the College of American Pathologists. Ongoing research and development commitments continue to augment Agendia"s ability to accurately predict breast cancer recurrence and sub-typing, and help physicians tailor individual treatment plans to their patients. Agendia"s goal is to provide women with answers to crucial treatment questions, such as how their breast cancer will respond to targeted therapies or various chemotherapy regimens. Agendia B.V.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009